Primary (AL) amyloidosis with gastrointestinal involvement

Lone Galmstrup Madsen; Peter Gimsing; Frank V Schiødt

doi:10.1080/00365520902783717

Primary (AL) amyloidosis with gastrointestinal involvement

Lone Galmstrup Madsen, Peter Gimsing, Frank V Schiødt

Teaching

24 Citations (Scopus)

Abstract

OBJECTIVE: Immunoglobulin light-chain (AL) amyloidosis is a rare disease that can affect several organs. The aim of this study was to characterize patients with gastrointestinal manifestations of AL amyloidosis, in terms of symptoms, biochemistry, and outcome. MATERIAL AND METHODS: Retrospectively, patients with AL amyloidosis admitted for evaluation of malabsorption in a Department of Gastroenterology between January 2000 and December 2006 were identified. RESULTS: A total of 11 patients (4 F, age 60 years, median (range) 50-69) were included in the study. Gastrointestinal amyloidosis was histologically verified in all patients. All patients had gastrointestinal symptoms, 8 of them prior to establishment of diagnosis. Median (range) delay from initial symptoms to diagnosis was 7 (0-24) months. The most prominent symptom was weight loss (n=10) averaging 7 (0-25) kg, followed by diarrhea (n=5). Steatorrhea (2 mild, 1 moderate, 1 severe) was found in 4 of 7 patients examined. At presentation, 9 patients had hypoalbuminemia and 6 patients had anemia. Three patients were treated with home parenteral nutrition. Five patients received conventional chemotherapy (oral melphalan and prednisone) and 5 patients underwent high-dose melphalan and autologous stem-cell transplantation. Five patients died within the observation period, at a median of 10 (3-36) months after the diagnosis was established. Non-survivors tended to have lower albumin levels on admission and more involvement of other organs compared to survivors. CONCLUSIONS: Most patients with gastrointestinal AL amyloidosis experience weight loss and all have signs of malabsorption. Despite treatment the prognosis is grave.

Original language	English
Journal	Scandinavian Journal of Gastroenterology
Volume	44
Issue number	6
Pages (from-to)	708-11
Number of pages	3
ISSN	0036-5521
DOIs	https://doi.org/10.1080/00365520902783717
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/00365520902783717

Cite this

@article{e0e83db0365911df8ed1000ea68e967b,

title = "Primary (AL) amyloidosis with gastrointestinal involvement",

abstract = "OBJECTIVE: Immunoglobulin light-chain (AL) amyloidosis is a rare disease that can affect several organs. The aim of this study was to characterize patients with gastrointestinal manifestations of AL amyloidosis, in terms of symptoms, biochemistry, and outcome. MATERIAL AND METHODS: Retrospectively, patients with AL amyloidosis admitted for evaluation of malabsorption in a Department of Gastroenterology between January 2000 and December 2006 were identified. RESULTS: A total of 11 patients (4 F, age 60 years, median (range) 50-69) were included in the study. Gastrointestinal amyloidosis was histologically verified in all patients. All patients had gastrointestinal symptoms, 8 of them prior to establishment of diagnosis. Median (range) delay from initial symptoms to diagnosis was 7 (0-24) months. The most prominent symptom was weight loss (n=10) averaging 7 (0-25) kg, followed by diarrhea (n=5). Steatorrhea (2 mild, 1 moderate, 1 severe) was found in 4 of 7 patients examined. At presentation, 9 patients had hypoalbuminemia and 6 patients had anemia. Three patients were treated with home parenteral nutrition. Five patients received conventional chemotherapy (oral melphalan and prednisone) and 5 patients underwent high-dose melphalan and autologous stem-cell transplantation. Five patients died within the observation period, at a median of 10 (3-36) months after the diagnosis was established. Non-survivors tended to have lower albumin levels on admission and more involvement of other organs compared to survivors. CONCLUSIONS: Most patients with gastrointestinal AL amyloidosis experience weight loss and all have signs of malabsorption. Despite treatment the prognosis is grave.",

author = "Madsen, {Lone Galmstrup} and Peter Gimsing and Schi{\o}dt, {Frank V}",

note = "Keywords: Aged; Amyloidosis; Female; Gastrointestinal Diseases; Humans; Immunoglobulin Light Chains; Malabsorption Syndromes; Male; Middle Aged; Paraproteinemias; Retrospective Studies Times Cited: 1ArticleEnglishSchiodt, F. VBispebjerg Hosp, Clin Internal Med 1, Bispebjerg Bakke 23, DK-2400 Copenhagen, NV, DenmarkCited References Count: 19447NWTAYLOR & FRANCIS ASKARL JOHANS GATE 5, NO-0154 OSLO, NORWAYOSLO",

year = "2009",

doi = "10.1080/00365520902783717",

language = "English",

volume = "44",

pages = "708--11",

journal = "Scandinavian Journal of Gastroenterology",

issn = "0036-5521",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Primary (AL) amyloidosis with gastrointestinal involvement

AU - Madsen, Lone Galmstrup

AU - Gimsing, Peter

AU - Schiødt, Frank V

N1 - Keywords: Aged; Amyloidosis; Female; Gastrointestinal Diseases; Humans; Immunoglobulin Light Chains; Malabsorption Syndromes; Male; Middle Aged; Paraproteinemias; Retrospective Studies Times Cited: 1ArticleEnglishSchiodt, F. VBispebjerg Hosp, Clin Internal Med 1, Bispebjerg Bakke 23, DK-2400 Copenhagen, NV, DenmarkCited References Count: 19447NWTAYLOR & FRANCIS ASKARL JOHANS GATE 5, NO-0154 OSLO, NORWAYOSLO

PY - 2009

Y1 - 2009

N2 - OBJECTIVE: Immunoglobulin light-chain (AL) amyloidosis is a rare disease that can affect several organs. The aim of this study was to characterize patients with gastrointestinal manifestations of AL amyloidosis, in terms of symptoms, biochemistry, and outcome. MATERIAL AND METHODS: Retrospectively, patients with AL amyloidosis admitted for evaluation of malabsorption in a Department of Gastroenterology between January 2000 and December 2006 were identified. RESULTS: A total of 11 patients (4 F, age 60 years, median (range) 50-69) were included in the study. Gastrointestinal amyloidosis was histologically verified in all patients. All patients had gastrointestinal symptoms, 8 of them prior to establishment of diagnosis. Median (range) delay from initial symptoms to diagnosis was 7 (0-24) months. The most prominent symptom was weight loss (n=10) averaging 7 (0-25) kg, followed by diarrhea (n=5). Steatorrhea (2 mild, 1 moderate, 1 severe) was found in 4 of 7 patients examined. At presentation, 9 patients had hypoalbuminemia and 6 patients had anemia. Three patients were treated with home parenteral nutrition. Five patients received conventional chemotherapy (oral melphalan and prednisone) and 5 patients underwent high-dose melphalan and autologous stem-cell transplantation. Five patients died within the observation period, at a median of 10 (3-36) months after the diagnosis was established. Non-survivors tended to have lower albumin levels on admission and more involvement of other organs compared to survivors. CONCLUSIONS: Most patients with gastrointestinal AL amyloidosis experience weight loss and all have signs of malabsorption. Despite treatment the prognosis is grave.

AB - OBJECTIVE: Immunoglobulin light-chain (AL) amyloidosis is a rare disease that can affect several organs. The aim of this study was to characterize patients with gastrointestinal manifestations of AL amyloidosis, in terms of symptoms, biochemistry, and outcome. MATERIAL AND METHODS: Retrospectively, patients with AL amyloidosis admitted for evaluation of malabsorption in a Department of Gastroenterology between January 2000 and December 2006 were identified. RESULTS: A total of 11 patients (4 F, age 60 years, median (range) 50-69) were included in the study. Gastrointestinal amyloidosis was histologically verified in all patients. All patients had gastrointestinal symptoms, 8 of them prior to establishment of diagnosis. Median (range) delay from initial symptoms to diagnosis was 7 (0-24) months. The most prominent symptom was weight loss (n=10) averaging 7 (0-25) kg, followed by diarrhea (n=5). Steatorrhea (2 mild, 1 moderate, 1 severe) was found in 4 of 7 patients examined. At presentation, 9 patients had hypoalbuminemia and 6 patients had anemia. Three patients were treated with home parenteral nutrition. Five patients received conventional chemotherapy (oral melphalan and prednisone) and 5 patients underwent high-dose melphalan and autologous stem-cell transplantation. Five patients died within the observation period, at a median of 10 (3-36) months after the diagnosis was established. Non-survivors tended to have lower albumin levels on admission and more involvement of other organs compared to survivors. CONCLUSIONS: Most patients with gastrointestinal AL amyloidosis experience weight loss and all have signs of malabsorption. Despite treatment the prognosis is grave.

U2 - 10.1080/00365520902783717

DO - 10.1080/00365520902783717

M3 - Journal article

C2 - 19242859

SN - 0036-5521

VL - 44

SP - 708

EP - 711

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

IS - 6

ER -

Primary (AL) amyloidosis with gastrointestinal involvement

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this